Affiliations: [a] China-Japan Union Hospital of Jilin University, Changchun, Jilin, China | [b] Beihua University Attached Hospital, Jilin, Jilin, China | [c] The People’s Hospital of Jilin Province, Changchun, Jilin, China | [d] Suqian Affiliated Hospital of Xuzhou Medical University, Suqian, Jiangsu, China | [e] The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Correspondence:
[*]
Corresponding authors: Jiayu Zhang or Yang Yang, China-Japan Union Hospital of Jilin University; Jinzhou Zhu, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. E-mail: [email protected].
Abstract: BACKGROUND: Recent evidence support that netrin-1 involves in colorectal carcinogenesis. OBJECTIVE: This study was to evaluate the performance of serum netrin-1 for detection of colorectal cancer (CRC) in both clinical/screening sets. METHODS: A total of 115 consecutive patients with CRC and matched healthy controls were included in Clinical Set. Fifty subjects with CRC, 50 subjects with advanced adenoma (AA), and 150 matched control participants free of neoplasia were included in Screening Set. RESULTS: In Clinical set, subjects with CRC presented higher levels of serum netrin-1 (513.9 ± 22.6 pg/mL) than controls (347.8 ± 20.3 pg/mL, p< 0.0001). Similar in Screening set, serum netrin-1 was higher in CRC (644.5 ± 37.0 pg/mL, both p< 0.0001), compared with controls (407.7 ± 14.8 pg/mL) and AA (416.5 ± 18.5 pg/mL). However, there was no difference between controls and AA (p= 0.752). Compared with the low netrin-1 group, the high group presented increased risk of CRC (Clinical set: OR = 4.300, p< 0.001; Screening set: OR = 7.731, p< 0.001). ROC curve of netrin-1 was developed to detect CRC (Clinical set: AUC 0.703; Screening set: AUC 0.759). CONCLUSIONS: It suggests netrin-1 as a potential biomarker for CRC detection.
